FDA filing acceptance and priority review received for SH-111

Shorla Oncology have submitted, and the US Food and Drug Administration (‘FDA’) have accepted for filing, its application for its SH-111 oncology drug designed to treat T-cell leukemia. SH-111 is a lifesaving treatment that is often in shortage and the company looks forward to working closely with FDA to bring this much needed product to market later this year.

Read more at: https://www.businesswire.com/news/home/20210423005122/en/Shorla-Pharma-Announces-FDA-Filing-Acceptance-and-Priority-Review-for-T-cell-Leukemia-Treatment